Verona Pharma PLC Result of AGM

 
TIDMVRP 
 
Verona Pharma plc 
 
                      ("Verona Pharma" or the "Company") 
 
                                 Result of AGM 
 
27 June 2016, Cardiff - Verona Pharma plc (AIM: VRP), the drug development 
company focused on first-in-class medicines to treat respiratory diseases, 
announces that all resolutions proposed at the Annual General Meeting (AGM) 
held today were duly passed. 
 
A presentation on Verona Pharma made by its Chief Executive Officer, Dr. 
Jan-Anders Karlsson, will be available to view on the Company's website 
www.veronapharma.com. No new material information is provided. 
 
                                    -Ends- 
 
For further information please contact: 
 
Verona Pharma plc                      Tel: +44 (0)20 3283 4200 
 
Jan-Anders Karlsson, Chief Executive 
Officer 
 
N+1 Singer                             Tel: +44 (0)20 7496 3000 
 
Aubrey Powell / Jen Boorer 
 
FTI Consulting                         Tel: +44 (0)20 3727 1000 
 
Simon Conway/Stephanie Cuthbert 
 
Notes to Editors 
 
About Verona Pharma plc 
 
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company 
focused on the development of innovative prescription medicines to treat 
respiratory diseases with significant unmet medical needs, such as chronic 
obstructive pulmonary disease (COPD), asthma and cystic fibrosis. 
 
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in phase 
II trials as a nebulised treatment for acute exacerbations of COPD in the 
hospital setting.  The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and 
therefore has both bronchodilator and anti-inflammatory effects, which are 
essential to the improvement of patients with COPD and asthma. 
 
Verona Pharma is also building a broader portfolio of RPL554-containing 
products to maximise its benefit to patients and its value.  This includes the 
very significant markets for COPD and asthma maintenance therapy.  The Company 
is also exploring the potential of the drug in different diseases, such as 
cystic fibrosis, where it is in pre-clinical testing and has recently received 
a Venture and Innovation Award from the Cystic Fibrosis Trust. 
 
About Chronic Obstructive Pulmonary Disease (COPD) 
 
Sixty-five million people worldwide suffer from moderate to severe COPD and the 
World Health Organisation (WHO) expects COPD to be the 3rd leading cause of 
death globally by 2020.  It is the only major chronic disease with increasing 
mortality.  Currently available drugs are aimed at long-term maintenance 
therapy, with the market dominated by large pharma.  Despite the wide 
availability of these therapies, COPD patients suffer acute periods of 
worsening symptoms (exacerbations), which cause, in the US alone, some 1.5 
million A&E visits, 726,000 hospitalisations and 120,000 deaths per annum. 
 
Bronchodilating therapy is considered to be the standard of care, and agents 
can be administered via handheld devices such as metered dose inhaler (MDI), 
dry powder inhaler (DPI) and by nebulisers.  The nebulised bronchodilator 
market was worth about $1 billion in 2014 in the US.1  RPL554 is being 
developed by Verona Pharma as an add-on therapy to the "Standard of Care" with 
the objectives of providing rapid and pronounced improvement in lung function, 
reduced symptoms and both shortened duration of hospital stays and reduced 
re-admission rates 30 days after discharge from hospital.  Studies to date on 
RPL554 have demonstrated that it has a strongly differentiated 3-way mode of 
action, being: (1) bronchodilation (the relaxation of smooth muscle in the 
airway); (2) anti-inflammatory effects on cells and (3) ion channel activation 
in epithelial cells, with increased mucociliary clearance of the airway. 
 
1 IMS Consulting Group market research 2014 
 
 
 
END
(END) Dow Jones Newswires
June 27, 2016 08:42 ET (12:42 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024